bf/NASDAQ:CLRB_icon.jpeg

NASDAQ:CLRB

Cellectar Biosciences, Inc.

  • Stock

0.26

+5.01%

−4.80

USD last updated 05/08 01:57:14

Last Close

5.06

04/08 20:55

Market Cap

84.24M

Beta: 1.17

Volume Today

359.90K

Avg: 55.21K

PE Ratio

−1.03

PFCF: −1.36

OverviewFinancialsAPI

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

    Description

    Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malign...Show More

    Excel Tearsheet

    Earnings

    Earnings per Share (Estimate*)

    -20-15-10-52018-05-112020-05-072022-05-102024-03-272024-10-29

    Revenue (Estimate*)

    50K100K150K200K250K300K350K2018-05-112020-05-072022-05-102024-03-272024-10-29

    *Estimate based on analyst consensus